Regeneration of Acutely Injured Nerves With Temporary Electrical Stimulation

A novel temporary peripheral nerve stimulation system that delivers a single dose of electrical stimulation therapy for 1 hour will be evaluated for safety and effectiveness.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Nerve Injury

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Alberta Hospital, Edmonton, Alberta, Canada

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Peripheral nerve injury

Exclusion criteria

Peripheral neuropathy
Patients with any active implanted device

Treatment and study plan

Temporary Peripheral Nerve Stimulation System

Device

Single use medical device. Therapy consists of single, 1 hour dose of electrical stimulation delivered proximal to injury site.

Sham Temporary Peripheral Nerve Stimulation System

Device

Single use medical device. Sham treatment consists of single, 1 hour dose of sham stimulation.

Primary outcomes

Sensory recovery

Time frame: 6 months
Cumulative incidence of adverse events

Time frame: 6 months

Study contacts

Contact information is provided by the study sponsor or research team.

Tracy Cameron, PhD

CONTACT

[email protected]

905-206-0466

Sponsors and collaborators

Lead sponsor

Epineuron Technologies Inc.

Industry

Registry information

Acronym: REGAIN

Important dates

Study start: 2023
Primary completion: 2026
Study completion: 2026
First posted: Feb 9, 2023
Registry last updated: Mar 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting